跳转至内容
Merck

SML1227

Sigma-Aldrich

Tavaborole

≥95% (HPLC)

别名:

1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, AN-2690, AN2690

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C7H6BFO2
分子量:
151.93
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥95% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

−20°C

InChI

1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2

InChI 密鑰

LFQDNHWZDQTITF-UHFFFAOYSA-N

相关类别

一般說明

Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.

生化/生理作用

Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3′ adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
Toledo-Bahena ME, et al.
J. Drugs Dermatol., 13(9), 1124-1132 (2014)
Spotlight on tavaborole for the treatment of onychomycosis
Jinna S and Finch J
Drug design, development and therapy, 9, 6185-6185 (2015)
Tavaborole for the treatment of onychomycosis
Elewski BE and Tosti A
Expert Opinion on Pharmacotherapy, 15(10), 1439-1448 (2014)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门